The Evidence-Based Management (EBM) portfolio dashboard, listed in Appendix B of Evolve: The Operating Model AI Demands (Hodgson, 2026), is a practical tool for executive teams managing a portfolio of products in an environment where AI has changed both what is possible and what investment decisions require. It structures portfolio choices around four empirical measures drawn from the Evidence-Based Management framework (Scrum.org, 2024): what customers value now, what they could value in the future, how quickly the organisation can respond to both, and how well it has maintained the capacity to do so. Current Value, Unrealised Value, Time to Market, and Ability to Innovate do not replace financial analysis. They provide the evidence base that financial analysis requires to be meaningful at the product level. Chapter 10 of Evolve (Hodgson, 2026) sets out the investment decision logic that maps EBM data to portfolio postures; Chapter 7 covers the quarterly review through which those decisions are made.
In Brief
- Portfolio investment decisions made without empirical data on product outcomes produce two systematic failure modes: continued funding of products that customers have stopped valuing, and termination of products generating genuine value that resist financial measurement.
- The EBM portfolio dashboard structures decisions across four empirical measures — Current Value, Unrealised Value, Time to Market, and Ability to Innovate — making each decision defensible, consistent, and reversible.
- This page specifies what to collect, at what cadence, and what the evidence means for the four investment postures available at the quarterly portfolio review: persevere, pivot, pause, or pull.
Portfolio investment decisions made without empirical data on product outcomes consistently produce one of two failure modes. The first is continued investment in products that customers have stopped valuing, sustained by internal advocacy and sunk-cost reasoning rather than external evidence. The second is termination of products that are producing genuine customer outcomes but are difficult to measure in financial terms. The EBM portfolio dashboard is designed to prevent both, by specifying what data to collect, at what frequency, and what that data means for decisions about which products to fund, which to redirect, which to pause, and which to pull.
Portfolio investment decisions require consistent criteria applied to every product
The dashboard operates at the portfolio level, not the product level. Its purpose is to give an executive team the data to make consistent investment decisions across a set of products, applying the same criteria in the same way. Each product in the portfolio is assessed against all four value areas at a defined cadence. Assessments are not audits; they are structured conversations informed by data, designed to surface the evidence an executive needs to distinguish products performing as intended from those requiring a different approach.
The dashboard does not predict outcomes. It describes current state with enough fidelity to identify which direction the evidence points. A product generating strong Current Value with high Unrealised Value and improving Time to Market warrants continued or increased investment. A product with declining Current Value, low Unrealised Value, and deteriorating Ability to Innovate has produced all available signal that resources should be redirected. Chapter 10 of Evolve (Hodgson, 2026) sets out the investment decision logic that maps EBM data to portfolio choices. This page specifies how to collect that data and what to look for in the result.
Current Value
Current Value measures the worth the product is delivering to customers and stakeholders now. It answers a single question: given what the organisation is producing and delivering, how much genuine value are customers experiencing?
Data sources
Customer outcome data is the primary source. Net Promoter Score, customer satisfaction ratings, and direct customer feedback through structured channels all contribute. Usage depth matters as much as access frequency: task completion rates, feature adoption, and session duration on core workflows indicate whether customers are deriving value, not just logging in. Revenue and retention metrics apply where the product is commercial. For internal products, the equivalent measure is whether the product reduces cost or removes friction for its users, tracked through time-on-task data and error rates rather than satisfaction scores alone.
Employee satisfaction with the product team is a secondary indicator. Teams building products that are genuinely valued operate differently from those defending a product that has lost its reason for existence. High attrition, difficulty hiring into product roles, and poor engagement scores are often earlier signals of declining Current Value than the customer data itself.
Reporting cadence
Product teams review core customer satisfaction metrics monthly; the portfolio review aggregates them quarterly. Usage data is continuous, surfaced in a weekly team dashboard and summarised at the monthly product review. Revenue and retention data follows the finance function’s reporting cadence, typically monthly, and feeds into the quarterly EBM review rather than running as a separate conversation.
Interpretation
The EBM portfolio dashboard does not read Current Value data in isolation from its investment context. Before any posture decision, the quarterly review tests the data against the investment hypothesis for that product: the four-sentence specification that states the rationale for the investment, the evidence expected within the first review cycle, the threshold that justifies continued funding, and the decision rule that establishes what happens when the evidence does not arrive (Hodgson, 2026). The decision rule, when triggered, applies the four-explanation diagnostic. The diagnostic identifies four possible explanations: the measures are wrong, the Product Goal is wrong, both are wrong, or the organisation chose lagging indicators whose evidence window has not yet closed.
Current Value data warrants a persevere decision when satisfaction metrics are stable or improving and usage depth is increasing. It warrants investigation when satisfaction scores are stable but usage is declining; when this pattern appears, customers are not actively dissatisfied but are finding alternatives. When satisfaction is declining and usage is contracting simultaneously across two or more review periods, and the four-explanation diagnostic rules out a measurement gap or lagging indicator, the posture is pivot or pull.
The investment implication of strong Current Value is retention of funding at current levels as a minimum. High Current Value combined with positive signals across the other three areas is the condition for an increase. Declining Current Value confirmed as genuine value loss is the primary driver of a pull recommendation; pull is triggered by the Product Manager and decided by the executive at the quarterly portfolio review (Hodgson, 2026). Whether the recommendation is pivot or pull depends on the Unrealised Value reading: a product with declining Current Value but high Unrealised Value is a pivot candidate; a product with declining Current Value and low Unrealised Value has no credible path to a different outcome.
Unrealised Value
Unrealised Value measures the potential future value the product could deliver if it fully met the needs of its intended customer base. It answers a different question from Current Value: how much of the available opportunity has this product captured, and how much remains?
Data sources
Market share data provides the clearest view of Unrealised Value for commercial products. The gap between current customer penetration and total addressable market is the most direct indicator of what remains to be captured. For internal products, the equivalent is the proportion of eligible users who have adopted the product at the level it was designed for. A product built for 5,000 users with 800 active users at intended depth has substantial Unrealised Value, provided those 4,200 non-users represent a genuine opportunity rather than a signal that the product is not fit for purpose.
Customer satisfaction gap analysis is the complementary source: the difference between what customers say they need and what the product currently provides. This data comes from customer interviews, feature request volumes and satisfaction scores by use case, and competitive intelligence showing what alternatives offer that the product does not.
Reporting cadence
Unrealised Value analysis is conducted quarterly as part of the portfolio review. It is not a continuous metric in the way Current Value is, because the market context it measures changes slowly enough that more frequent review produces noise rather than signal. The exception is competitive displacement: where a competitor has made a significant move that changes the opportunity available to the product, a triggered review outside the quarterly cadence is appropriate.
Interpretation
High Unrealised Value is not automatically an instruction to invest more. It is evidence of an opportunity, and the decision to pursue it depends on whether Time to Market and Ability to Innovate indicate the product team can realistically capture it. A product with high Unrealised Value but consistently poor Time to Market and declining Ability to Innovate needs structural change before any investment increase.
Declining Unrealised Value requires the most careful interpretation. If Unrealised Value is declining because the product is capturing its market — current penetration is increasing toward the ceiling — that is a positive signal. If it is declining because the ceiling itself is lower than originally estimated, or because the customer need has shifted, that is a pull signal: the Product Goal the investment was funded to pursue is no longer achievable, and the opportunity has either been reached or has closed. Distinguishing between the two requires the customer satisfaction gap data, not the market share data alone.
Time to Market
Time to Market measures the organisation’s ability to deliver new capabilities to customers quickly. It answers the question: how much time passes between identifying a customer need and putting a working response in customers’ hands?
Data sources
Cycle time is the primary measure: the elapsed time from work start to customer delivery. Lead time, which includes the time work spends waiting before it starts, provides a fuller picture and is more useful for identifying where in the system delays are being produced. Release frequency and deployment frequency indicate how regularly the team is delivering to production, which is the precondition for short cycle times.
Defect escape rate matters here because defects in production extend the effective time to market for the work that follows them. A team spending significant capacity on unplanned defect remediation has less capacity to respond to customer needs. Customer wait time, the elapsed time from when a customer identifies a need to when they receive a working solution, most directly reflects the customer experience of Time to Market.
Reporting cadence
Time to Market metrics are available continuously at the product team level and reviewed monthly at the product review. Portfolio-level review is quarterly, with trend data across at least three prior periods to distinguish a temporary variation from a systemic change in delivery performance.
Interpretation
When a product with stable or improving Current Value is also improving on Time to Market, the team is responding to customer needs effectively. When Time to Market is improving but Current Value is declining, the team is delivering faster but not addressing the customer need. At that point, the product’s direction, not its delivery capability, requires examination.
Deteriorating Time to Market in a product with high Unrealised Value identifies a delivery system constraint, not a product direction problem. The four-explanation diagnostic will confirm a lagging-indicator condition: the delivery system cannot produce evidence at the pace the investment hypothesis requires. The correct posture is pause: reduce new feature investment velocity while the delivery system constraint is addressed. Persistent, worsening Time to Market across multiple review periods, absent a clear structural cause, indicates a systemic problem in the delivery model that additional feature funding will not resolve.
Ability to Innovate
Ability to Innovate measures the organisation’s capacity to produce new capabilities that better serve customer needs, including needs the customer has not yet articulated. It answers the question: is the team able to respond to emerging opportunities, or is it constrained by the weight of what it has already built?
Data sources
Technical debt ratio is the primary indicator: the proportion of team capacity spent maintaining existing functionality versus building new capability. A team spending more than 30 to 40% of capacity on maintenance, defect remediation, and technical remediation is signalling that its Ability to Innovate is being consumed by its past decisions. Innovation rate tracks the same dynamic from the output side; it measures the proportion of delivery that represents new capability rather than maintenance, compliance, or remediation work.
Unplanned work percentage, the proportion of team capacity consumed by urgent and unscheduled demands, is the leading indicator of trouble ahead. High unplanned work volume is the early warning that technical debt or operational fragility is beginning to dominate the system before it appears in cycle time or delivery rate. Employee capability development investment, measured as the proportion of time the team spends in deliberate learning and experimentation, completes the indicator set.
Reporting cadence
Ability to Innovate indicators are reviewed monthly at the product level and quarterly at the portfolio level. Technical debt ratio and innovation rate benefit from trend analysis over six to twelve months because they change slowly and short-term variation is not meaningful.
Interpretation
Declining Ability to Innovate in a product with high Current Value is the pause signal. The product is performing, but the team’s capacity to sustain that performance is being consumed. Continuing to invest in features without resolving the technical constraints will produce short-term output at the cost of medium-term capability. The Product Manager triggers the pause; the executive decides it at the quarterly portfolio review. The pause carries a timebox. The condition for reinvestment in features is a defined improvement in Ability to Innovate metrics, not a fixed calendar date; work that continues during a pause without a clear delivery objective is more likely to be waste (Hodgson, 2026).
Strong Ability to Innovate in a product with low Current Value warrants investigation rather than immediate action; the team has capacity, but it is not producing outcomes customers value. This is most often a product direction problem rather than a team capability problem, and the appropriate response is to examine the connection between what the team is building and what customers need.
The four value areas examined in sequence surface the portfolio decision
The four value areas are not independent. The interactions between them produce the most useful signals for portfolio investment decisions, and the quarterly review is designed to read them in sequence.
The sequence in which the four areas are examined matters because each one frames the next. Current Value is examined first because it establishes the foundation. A product with strong Current Value has earned the right to have its future examined. A product with declining Current Value is already facing a stop consideration, and the evidence from the other three areas determines whether that consideration is immediate or deferred pending a defined intervention.
Unrealised Value is examined second because it defines the opportunity ceiling. The investment question is whether the opportunity the product is addressing is large enough to justify continued investment at any level — not whether to invest at all. A product with declining Current Value and low Unrealised Value has no credible path to a different outcome without a fundamental change in what it is for.
Time to Market comes third: can the team actually reach the opportunity the data reveals? High Unrealised Value combined with poor Time to Market is a delivery system problem, not a product problem, and the investment decision must reflect that distinction. Funding product development in a team that cannot deliver at the speed the market requires produces output without outcomes.
Ability to Innovate is examined last, and it answers the question most executives defer: how long can current performance be sustained? A team with declining Ability to Innovate cannot sustain the delivery performance its current metrics show indefinitely. The quarterly review uses Ability to Innovate data to identify which products are on a trajectory toward delivery constraint before that constraint becomes visible in Current Value.
Tensions between areas are more informative than alignment. When all four areas are positive, the decision is straightforward: persevere, and review whether investment should increase. When areas are in tension, the pattern of that tension identifies the appropriate decision. In all cases, the four-explanation diagnostic is applied before acting: the posture is chosen on the basis of which explanation fits, not the surface-level pattern of the data alone.
Strong Current Value combined with high Unrealised Value, poor Time to Market, and declining Ability to Innovate signals that the product has an audience and an opportunity but the delivery system is constraining both. The decision is to pause new feature investment and resolve the delivery system constraints before they produce a Current Value decline. The Product Manager triggers the pause; the executive decides it at the quarterly portfolio review.
Declining Current Value combined with high Unrealised Value, strong Time to Market, and strong Ability to Innovate signals that the product can deliver and innovate, but is not currently meeting customer needs. The decision is to pivot; the team has the capability but the direction requires change. Pivot sits with the Product Manager: the goal stays and the plan changes.
Strong Current Value combined with declining Unrealised Value, strong Time to Market, and strong Ability to Innovate signals that the product has captured its market. The opportunity the investment was funded to pursue has been reached; what remains is insufficient to justify continued growth investment. The decision is to pull: the outcome has been achieved and the product has reached maturity (Hodgson, 2026). Pull is triggered by the Product Manager and decided by the executive at the quarterly portfolio review.
Declining Current Value combined with low Unrealised Value, poor Time to Market, and declining Ability to Innovate means all four areas produce the same signal. The four-explanation diagnostic confirms the Product Goal is wrong with no viable pivot, or the product direction no longer serves the portfolio strategy. The decision is to pull. Further investment has no credible path to a different outcome.
Worked example: a quarterly review across five products
The following example applies the EBM portfolio dashboard to a portfolio of five products at the quarterly review. Each product receives a decision: persevere, pivot, pause, or pull.
Product A — Customer Onboarding Portal
Current Value data is strong: NPS has increased from 34 to 47 over three quarters and task completion rate has improved from 61 to 79%. Unrealised Value is moderate: market penetration sits at 63% of eligible customers, and satisfaction gap analysis indicates that complex-case customers remain underserved. Time to Market is strong: cycle time has decreased from 18 days to 11 days over two quarters, and release frequency is fortnightly. Ability to Innovate is stable at 72% innovation rate, with technical debt ratio holding at 21%.
Before the quarterly review, the investment hypothesis for Product A establishes the measurement frame in four sentences. The product team is investing to reduce customer abandonment during onboarding, driven by a 21-day approval time that NPS data confirms is the primary friction point. Within two Sprints, the NPS for customers using the redesigned flow exceeds 40 and task completion for complex onboarding scenarios exceeds 72%. Funding continues while both measures trend toward the Product Goal targets; if neither moves within two review cycles, the Product Manager applies the four-explanation diagnostic before any posture decision.
The primary signal is Current Value: the product is delivering measurably better outcomes and the delivery system is improving. The moderate Unrealised Value in the complex-case segment warrants a focused product direction conversation, but does not change the investment level. Decision: persevere.
Product B — Regulatory Reporting Module
Current Value has deteriorated significantly. Satisfaction scores have dropped from 58 to 39 over two quarters. Usage has contracted as teams develop manual workarounds for high-complexity reports rather than using the module. Unrealised Value analysis indicates the market need is fully served by three competing internal tools built independently in response to the module’s limitations; the opportunity ceiling has closed entirely, not merely contracted. Time to Market is poor: cycle time averages 34 days, with high defect escape rates consuming 40% of team capacity. Ability to Innovate is critically low at 31% innovation rate, with 58% of capacity on maintenance and unplanned defect work.
Decision: pull. All four areas produce the same signal, and the Unrealised Value finding is definitive: the opportunity this product was built to address is no longer available to it. The four-explanation diagnostic confirms it: the Product Goal is wrong with no viable pivot, because the market opportunity has closed. The investment funds team capacity that will produce more value applied to products with genuine opportunity. Pull is triggered by the Product Manager and decided by the executive at the quarterly portfolio review.
Product C — AI-Assisted Case Management Tool
Current Value sits in the moderate range. Customer satisfaction is at 52 NPS, but usage depth is high among the 31% of eligible users who have adopted the tool. Unrealised Value is substantial — 69% of eligible users have not adopted the tool, and satisfaction gap analysis indicates the tool’s current capability addresses the primary user need effectively. Time to Market is the constraint: cycle time averages 29 days, release frequency is monthly, and the team’s primary bottleneck is the approval process for AI-generated outputs, which requires a manual review step that is not resourced to keep pace with delivery.
Decision: pause. The product direction is correct — the capability is delivering genuine value to users who have adopted it, and the Unrealised Value is real. The Time to Market data identifies the constraint. The four-explanation diagnostic confirms a lagging-indicator condition: the team’s delivery velocity is limited by the manual review process, which cannot match the team’s output rate. This is a value stream impediment for the Product COO, not a reason to revise the product direction. New feature investment is suspended while the Product COO redesigns the AI-output review process to match the team’s delivery rate. The pause carries a timebox: feature investment resumes when cycle time returns to below 15 days.
Product D — Mobile Field Inspection App
Current Value is stable. NPS is 61 and usage is broad across the eligible user base at 84% adoption. Unrealised Value is limited — the product has captured its market effectively, and the remaining 16% of non-users are in contexts where mobile access is genuinely unavailable. Time to Market is strong at nine-day average cycle time. Ability to Innovate has declined from 68 to 44% innovation rate over three quarters, with unplanned work percentage increasing from 12 to 31%. Technical debt ratio has reached 42%.
Decision: pull. The Current Value confirms a performing product; the Ability to Innovate data identifies a growing technical constraint. But the Unrealised Value data provides the governing signal: with 84% of eligible customers adopted and the remaining 16% in contexts where mobile access is genuinely unavailable, the product has reached the ceiling of its addressable market. The four-explanation diagnostic confirms the Product Goal — achieving broad field inspection coverage — has been achieved. Pausing to reduce technical debt would fund capability without opportunity. The outcome has been achieved and the product has reached maturity; the investment funds team capacity that will produce more value applied to growth-stage products. Pull is triggered by the Product Manager and decided by the executive.
Product E — Portfolio Analytics Platform
Current Value is strong and improving: NPS at 71, usage depth high across all user segments, and a measurable reduction in the time portfolio managers spend producing quarterly reviews: from 3.2 days to 0.8 days per review cycle. Unrealised Value is high — the platform currently serves the investment portfolio team but has been assessed as directly applicable to the program delivery and enterprise architecture functions, each representing a comparable adoption opportunity. Time to Market is strong at eight-day cycle time and weekly releases. Ability to Innovate is robust at 78% innovation rate with technical debt ratio at 18%.
All four areas are positive and the Unrealised Value finding indicates a material expansion opportunity (Hodgson, 2026). Decision: persevere with increased investment. The expansion to program delivery and enterprise architecture functions is approved. Team capacity increases by two senior engineers to support the platform’s extension to new user segments.
The dashboard makes portfolio investment decisions defensible, consistent, and reversible
Across these five products, the quarterly review produces two persevere decisions — Product A at current investment and Product E with an increase — two pull decisions, and one pause. Each decision is anchored to the value area that provides the primary evidence: Current Value drives the persevere for Product A; Unrealised Value and the four-explanation diagnostic confirm the pull for Product B and Product D; Time to Market — identified as a lagging-indicator delivery constraint — drives the pause for Product C; and the convergence of all four positive signals, including a substantial Unrealised Value finding, drives the investment increase for Product E.
The dashboard does not make the decision. It produces the evidence that makes the decision defensible, consistent, and reversible. Portfolio investment choices made through this mechanism can be revisited when the data changes; decisions made on advocacy, precedent, or funding inertia have no equivalent mechanism for correction (Scrum.org, 2024).
What this means for portfolio executives
- Investment decisions anchored to advocacy — internal sponsorship, sunk-cost reasoning, funding inertia — have no mechanism for correction when the underlying evidence changes. The EBM dashboard provides that mechanism by separating evidence collection from the decision itself, making both independently auditable at the next quarterly review.
- The four value areas carry the most decision-relevant information in tension, not alignment. A product where all four areas are positive has an unambiguous answer. A product where areas conflict surfaces the specific constraint: product direction, delivery system, or technical capacity. The portfolio review is most valuable in those cases, not the straightforward ones.
- Time to Market and Ability to Innovate are leading indicators. Declining performance in either area will appear in Current Value within one to two review cycles if not addressed. Portfolio executives who act on leading indicators spend less on remediation than those who wait for Current Value to confirm the problem.
- A pull decision requires declining Current Value confirmed as genuine value loss — or a market ceiling that has been reached — with no viable pivot available. A product with declining Current Value but high Unrealised Value is a pivot candidate, not a pull. Conflating the two produces premature termination of products that, with a change in direction, retain genuine opportunity.
- The quarterly cadence is what makes decisions reversible. A product paused with a defined condition for reinvestment — Ability to Innovate returning to above 60% innovation rate, for instance — has a re-entry mechanism. A product pulled under portfolio pressure has none.
References
- Hodgson, M. (2026). Evolve: The operating model AI demands. Zen Ex Machina.
- Scrum.org. (2024). The evidence-based management guide: Improving value delivery under conditions of uncertainty. Scrum.org. https://www.scrum.org/resources/evidence-based-management-guide
- Schwaber, K., & Sutherland, J. (2020). The Scrum guide: The definitive guide to Scrum: The rules of the game. Scrum.org. https://scrumguides.org/scrum-guide.html
